BIOMAT Database Logo BIOMAT Database Logo

Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. 1990

D A Herrington, and L Van de Verg, and S B Formal, and T L Hale, and B D Tall, and S J Cryz, and E C Tramont, and M M Levine
Department of Medicine, University of Maryland, Baltimore 21201.

A bivalent vaccine consisting of Salmonella typhi strain Ty21a containing the 120 MDa plasmid of Shigella sonnei and expressing both S. typhi and S. sonnei lipopolysaccharides (LPS) on its surface was previously shown to protect significantly against S. sonnei disease in experimental challenge studies. However, protective efficacy could not be reconfirmed in volunteers with five subsequent lots of vaccine. One vaccine lot which resembled the initial protective lots of vaccine in biochemical and serological tests, and by electron microscopy, was administered to 16 volunteers who ingested three doses of 10(9) organisms each. Antibody secreting cells (ASC) specific for S. sonnei LPS were detected in the blood of 100% of vaccines, but no protection of these vaccines was demonstrated during a S. sonnei challenge study. To assess the ability of the volunteer model to detect infection-derived immunity, six volunteers who had had clinical shigellosis due to S. sonnei two months earlier were rechallenged with wild-type S. sonnei, together with 12 controls. Prior infection provided 100% protection against febrile illness (p = 0.05) and diarrhea (p = 0.04), thereby validating the volunteer model for assessing Shigella vaccines.

UI MeSH Term Description Entries
D007070 Immunoglobulin A Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions. IgA,IgA Antibody,IgA1,IgA2,Antibody, IgA
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D004405 Dysentery, Bacillary DYSENTERY caused by gram-negative rod-shaped enteric bacteria (ENTEROBACTERIACEAE), most often by the genus SHIGELLA. Shigella dysentery, Shigellosis, is classified into subgroups according to syndrome severity and the infectious species. Group A: SHIGELLA DYSENTERIAE (severest); Group B: SHIGELLA FLEXNERI; Group C: SHIGELLA BOYDII; and Group D: SHIGELLA SONNEI (mildest). Shigellosis,Dysentery, Shiga bacillus,Dysentery, Shigella boydii,Dysentery, Shigella dysenteriae,Dysentery, Shigella dysenteriae type 1,Dysentery, Shigella flexneri,Dysentery, Shigella sonnei,Shigella Dysentery,Shigella Infection,Bacillary Dysentery,Dysenteries, Shigella,Dysenteries, Shigella boydii,Dysenteries, Shigella dysenteriae,Dysenteries, Shigella flexneri,Dysenteries, Shigella sonnei,Dysentery, Shigella,Infection, Shigella,Infections, Shigella,Shiga bacillus Dysentery,Shigella Dysenteries,Shigella Infections,Shigella boydii Dysenteries,Shigella boydii Dysentery,Shigella dysenteriae Dysenteries,Shigella dysenteriae Dysentery,Shigella flexneri Dysenteries,Shigella flexneri Dysentery,Shigella sonnei Dysenteries,Shigella sonnei Dysentery
D005069 Evaluation Studies as Topic Works about studies that determine the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. Critique,Evaluation Indexes,Evaluation Methodology,Evaluation Report,Evaluation Research,Methodology, Evaluation,Pre-Post Tests,Qualitative Evaluation,Quantitative Evaluation,Theoretical Effectiveness,Use-Effectiveness,Critiques,Effectiveness, Theoretical,Evaluation Methodologies,Evaluation Reports,Evaluation, Qualitative,Evaluation, Quantitative,Evaluations, Qualitative,Evaluations, Quantitative,Indexes, Evaluation,Methodologies, Evaluation,Pre Post Tests,Pre-Post Test,Qualitative Evaluations,Quantitative Evaluations,Report, Evaluation,Reports, Evaluation,Research, Evaluation,Test, Pre-Post,Tests, Pre-Post,Use Effectiveness
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody
D012485 Salmonella typhi A serotype of SALMONELLA ENTERICA which is the etiologic agent of TYPHOID FEVER. Salmonella enterica serovar Typhi,Salmonella typhosa

Related Publications

D A Herrington, and L Van de Verg, and S B Formal, and T L Hale, and B D Tall, and S J Cryz, and E C Tramont, and M M Levine
Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine.
June 1987, The Journal of infectious diseases,
D A Herrington, and L Van de Verg, and S B Formal, and T L Hale, and B D Tall, and S J Cryz, and E C Tramont, and M M Levine
Molecular analysis of variant plasmid forms of a bivalent Salmonella typhi-Shigella sonnei vaccine strain.
January 1991, Journal of clinical microbiology,
D A Herrington, and L Van de Verg, and S B Formal, and T L Hale, and B D Tall, and S J Cryz, and E C Tramont, and M M Levine
Construction of a stable and non-resistant bivalent vaccine candidate strain against Shigella flexneri 2a and Shigella sonnei.
January 1996, Chinese journal of biotechnology,
D A Herrington, and L Van de Verg, and S B Formal, and T L Hale, and B D Tall, and S J Cryz, and E C Tramont, and M M Levine
Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain.
December 1981, Infection and immunity,
D A Herrington, and L Van de Verg, and S B Formal, and T L Hale, and B D Tall, and S J Cryz, and E C Tramont, and M M Levine
Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine.
August 1992, The Journal of clinical investigation,
D A Herrington, and L Van de Verg, and S B Formal, and T L Hale, and B D Tall, and S J Cryz, and E C Tramont, and M M Levine
A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi.
May 2012, Vaccine,
D A Herrington, and L Van de Verg, and S B Formal, and T L Hale, and B D Tall, and S J Cryz, and E C Tramont, and M M Levine
Unusual lipopolysaccharide antigens of a Salmonella typhi oral vaccine strain expressing the Shigella sonnei form I antigen.
July 1984, The Journal of biological chemistry,
D A Herrington, and L Van de Verg, and S B Formal, and T L Hale, and B D Tall, and S J Cryz, and E C Tramont, and M M Levine
Intestinal immunoglobulin A responses in rabbits to a Salmonella typhi strain harboring a Shigella sonnei plasmid.
July 1982, Infection and immunity,
D A Herrington, and L Van de Verg, and S B Formal, and T L Hale, and B D Tall, and S J Cryz, and E C Tramont, and M M Levine
Bacterial ghost cell based bivalent candidate vaccine against Salmonella Typhi and Salmonella Paratyphi A: A prophylactic study in BALB/c mice.
September 2023, Vaccine,
D A Herrington, and L Van de Verg, and S B Formal, and T L Hale, and B D Tall, and S J Cryz, and E C Tramont, and M M Levine
Protective ribosomal preparation from Shigella sonnei as a parenteral candidate vaccine.
October 1991, Infection and immunity,
Copied contents to your clipboard!